- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Participating Faculty
The American Journal of Managed Care
This supplement to reviews current treatment options andtheir cost effectiveness for the management of benign prostatic hyperplasia in the context of commonage-associated comorbidities.
Faculty
- J. Curtis Nickel, MD, FRCSCProfessor Department of Urology Queen's University Kingston General Hospital Kingston, Ontario, Canada
- Kevin T. McVary, MD, FACSAssociate Professor of Urology Department of Urology Feinberg School of Medicine Northwestern School of Medicine Chicago, Illinois
- Michael P. O'Leary, MD, MPHAssociate Professor of Surgery Department of Surgery Harvard Medical School Senior Surgeon Division of Urology Brigham and Women's Hospital Boston, Massachusetts
- Gary M. Owens, MDVice President, Medical Management and Policy Independence Blue Cross Philadelphia, Pennsylvania
Faculty Disclosure
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programssponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.
These participants have declared the following affiliations with corporate organizations:
- Kevin T. McVary, MD, FACSConsultant for/Speaker's bureau for:GlaxoSmithKlineLilly ICOSMerckOrtho-McNeilPfizerSanofi-Aventis
- J. Curtis Nickel, MD, FRCSCGrant/Research support from:GlaxoSmithKlineMerck Frosst CanadaSanofi-AventisConsultant for:Boehringer IngelheimCanadaGlaxoSmithKline CanadaMerck Frosst CanadaSanofi-Aventis Canada
- Michael P. O'Leary, MD, MPHGrant/Research support from:GlaxoSmithKlineConsultant for:Boehringer IngelheimSanofi-Aventis
- Gary M. Owens, MDEmployee of:Independence Blue Cross
The American Journal of Managed Care,
A signed disclosure is on file at the offices of Jamesburg,New Jersey.
FUNDING
This publication was made possible by funding from Boehringer Ingelheim.
•••
The contents of this supplement may include information regarding the use of products that may be inconsistentoutside the approved labeling for these products in the United States. Physicians should note that the use of theseproducts outside current approved labeling is considered experimental and are advised to consult prescribing informationfor these products.
